Get your free ETF data sample from our comprehensive offerings. Start your free trial

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

ETF What's Up

You may unsubscribe at any time by clicking the “unsubscribe” link within the emailed newsletter. By signing up, you agree to our Privacy Policy and Terms and Conditions.

ETF IssuersVanEckCURE
CURE

VanEck Genomics and Healthcare Innovators UCITS ETF

The CURE Exchange Traded Fund (ETF) is provided by VanEck. It is built to track an index: MVIS Global Future Healthcare ESG Index. The CURE ETF provides physical exposure, so by buying it you actually own parts of all the 49 underlying holdings. The dividend policy is capitalization.

Advertisement

Advertisement

$22.03
N/A
Data as of 07/23/26
1D price range
N/A
52W price range
$19.26$24.14
YTD Perf.
-1.17%
YTD Flows
Annualized volatility
Fund AuM
€12M
Share class AuM
€12M
TTM Yield
-
Tracking Error
Tracking Difference
ISIN
IE000B9PQW54
TER
0.35%
Inception date
9/2/2022
Issuer
Replication method
Dividend policy
Compare similar ETFs
API
PerformanceDec 31, 2025 - Jul 23, 2026
-10%-5%0%5%10%JANMARMAYJUL
Flows
Join for free to unlock
Data as of 06/30/26
Healthcare
95.83%
Consumer Non-Cyclicals
2.88%
Technology
1.29%
Latest CURE news

No content available for this fund

FAQ about CURE

CURE is a Passive ETF. This ETF provides exposure to Equities.
CURE tracks the MVIS Global Future Healthcare ESG Index - USD, through a full replication replication method.
CURE carries a total expense ratio (TER) of 0.35%, indicating the annual cost for holding the fund.
CURE was introduced to the market on September 2, 2022. It trades on Finland, among other exchanges
VanEck Genomics and Healthcare Innovators UCITS ETF, CURE, is provided by VanEck. Learn more about VanEck here.
CURE oversees €12M in assets as of July 23, 2026.
CURE follows a capitalizing, meaning it reinvests income within the fund.
As of June 30, 2026, CURE has significant geographic allocations in USA, Germany and Australia.
As of June 30, 2026, CURE focuses largely on Healthcare, Consumer Non-Cyclicals and Technology.
As of June 30, 2026, CURE holds 49 positions in its portfolio, with 71.85% of assets concentrated in its top 15 holdings.
As of June 30, 2026, CURE top three holdings include Vertex Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. and Natera, Inc..
The base currency of CURE is USD.
Data as of 06/30/26
Vertex Pharmaceuticals, Inc.
8.15%
Regeneron Pharmaceuticals, Inc.
7.41%
Natera, Inc.
7.28%
Moderna, Inc.
6.12%
Veeva Systems, Inc.
5.81%
DexCom, Inc.
5.63%
Alnylam Pharmaceuticals, Inc.
5.08%
Illumina, Inc.
4.84%
Guardant Health, Inc.
4.62%
BioNTech SE
3.93%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight